» Articles » PMID: 34188135

Impact of Proton Therapy on Antitumor Immune Response

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 30
PMID 34188135
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy delivered using photons induces an immune response that leads to modulation of the tumor microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors in association with photon radiotherapy. At present, there is no publication on the radio-induced immune response after proton therapy. Balb/c mice bearing subcutaneous CT26 colon tumors were irradiated by a single fraction of 16.4 Gy using a proton beam extracted from a TR24 cyclotron. RNA sequencing analysis was assessed at 3 days post-treatment. Proton therapy immune response was monitored by flow cytometry using several panels (lymphoid, myeloid cells, lymphoid cytokines) at 7 and 14 days post-irradiation. RNA-Seq functional profiling identified a large number of GO categories linked to "immune response" and "interferon signaling". Immunomonitoring evaluation showed induced tumor infiltration by immune cells. This is the first study showing the effect of proton therapy on immune response. These interesting results provide a sound basis to assess the efficacy of a combination of proton therapy and immune checkpoint inhibitors.

Citing Articles

Rotationally Intensified Proton Lattice: A Novel Lattice Technique Using Spot-Scanning Proton Arc Therapy.

Lee J, Mumaw D, Liu P, Loving B, Sebastian E, Cong X Adv Radiat Oncol. 2024; 9(11):101632.

PMID: 39610800 PMC: 11603120. DOI: 10.1016/j.adro.2024.101632.


Three discipline collaborative radiation therapy (3DCRT) special debate: Systemic radiotherapy using targeted isotopes is the best hope for advancing curative radiation therapy.

Koontz B, Koritzinsky M, Zoberi J, Brown S, Ding X, Wong J J Appl Clin Med Phys. 2024; 25(11):e14533.

PMID: 39447139 PMC: 11539965. DOI: 10.1002/acm2.14533.


Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers.

Rykkelid A, Sinha P, Folefac C, Horsman M, Sorensen B, Soland T Sci Rep. 2024; 14(1):11569.

PMID: 38773258 PMC: 11109162. DOI: 10.1038/s41598-024-62272-z.


Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies.

Skalina K, Malachowska B, Sindhu K, Thompson M, Nehlsen A, Salgado L BJUI Compass. 2024; 5(3):334-344.

PMID: 38481668 PMC: 10927934. DOI: 10.1002/bco2.316.


Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell Carcinoma.

Chimote A, Lehn M, Bhati J, Mascia A, Sertorio M, Lamba M Cancers (Basel). 2024; 16(5).

PMID: 38473367 PMC: 10931005. DOI: 10.3390/cancers16051008.


References
1.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

2.
Zhang F, Manna S, Pop L, Chen Z, Fu Y, Hannan R . Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Semin Radiat Oncol. 2020; 30(2):129-138. DOI: 10.1016/j.semradonc.2019.12.009. View

3.
Kabiljo J, Laengle J, Bergmann M . From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. Cell Death Discov. 2020; 6:48. PMC: 7288254. DOI: 10.1038/s41420-020-0284-1. View

4.
Boustani J, Grapin M, Laurent P, Apetoh L, Mirjolet C . The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers (Basel). 2019; 11(6). PMC: 6627091. DOI: 10.3390/cancers11060860. View

5.
Paludan S, Reinert L, Hornung V . DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer. Nat Rev Immunol. 2019; 19(3):141-153. PMC: 7311199. DOI: 10.1038/s41577-018-0117-0. View